Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 438

1.

Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients.

Satta N, Pagano S, Montecucco F, Gencer B; Swiss HIV Cohort Study, Mach F, Kaiser L, Calmy A, Vuilleumier N.

J Infect. 2018 Feb;76(2):186-195. doi: 10.1016/j.jinf.2017.11.008. Epub 2017 Dec 14.

PMID:
29198606
2.

Infection-related and -unrelated malignancies, HIV and the aging population.

Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2016 Sep;17(8):590-600. doi: 10.1111/hiv.12359. Epub 2016 Feb 18.

3.

The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events.

Wandeler G, Kraus D, Fehr J, Conen A, Calmy A, Orasch C, Battegay M, Schmid P, Bernasconi E, Furrer H; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):302-9. doi: 10.1097/QAI.0000000000000864.

4.

Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period.

Aebi-Popp K, Kouyos R, Bertisch B, Staehelin C, Rudin C, Hoesli I, Stoeckle M, Bernasconi E, Cavassini M, Grawe C, Lecompte TD, Rickenbach M, Thorne C, Martinez de Tejada B, Fehr J; Swiss Mother and Child HIV Cohort Study; Swiss HIV Cohort Study.

HIV Med. 2016 Apr;17(4):280-8. doi: 10.1111/hiv.12299. Epub 2015 Aug 12.

5.

A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.

Wang H, El Maadidi S, Fischer J, Grabski E, Dickhöfer S, Klimosch S, Flannery SM, Filomena A, Wolz OO, Schneiderhan-Marra N, Löffler MW, Wiese M, Pichulik T, Müllhaupt B, Semela D, Dufour JF, Bochud PY, Bowie AG, Kalinke U, Berg T, Weber AN; East-German and Swiss Hepatitis C Virus Study Groups.

Hepatology. 2015 Nov;62(5):1375-87. doi: 10.1002/hep.28105. Epub 2015 Sep 28.

PMID:
26250868
6.

Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study.

Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group.

HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

7.

Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study.

Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M, Parczewski M, Lundgren JD, Mocroft A, Kirk O; EuroSIDA in EuroCoord.

HIV Med. 2015 Oct;16(9):533-43. doi: 10.1111/hiv.12254. Epub 2015 May 18.

8.

Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?

Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK; EuroSIDA in EuroCoord.

Liver Int. 2015 Nov;35(11):2384-91. doi: 10.1111/liv.12848. Epub 2015 Apr 29.

PMID:
25875966
9.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

10.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
11.

Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.

Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM, Doroana M, Battegay M, Gargalianos P, Mocroft A; EuroSIDA in EuroCOORD.

AIDS. 2014 Nov 13;28(17):2565-71. doi: 10.1097/QAD.0000000000000433.

PMID:
25574959
12.

Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.

Rosin C, Elzi L, Thurnheer C, Fehr J, Cavassini M, Calmy A, Schmid P, Bernasconi E, Battegay M; Swiss HIV Cohort Study.

HIV Med. 2015 May;16(5):319-25. doi: 10.1111/hiv.12203. Epub 2014 Oct 20.

13.

The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.

Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Kaiser L, Osthoff M, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2014 Aug 24;28(13):1885-9. doi: 10.1097/QAD.0000000000000379.

14.

Contact tracing investigation after professional exposure to tuberculosis in a Swiss hospital using both tuberculin skin test and IGRA.

Balmelli C, Zysset F, Pagnamenta A, Francioli P, Lazor-Blanchet C, Zanetti G, Zellweger JP.

Swiss Med Wkly. 2014 Aug 14;144:w13988. doi: 10.4414/smw.2014.13988. eCollection 2014.

15.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group.

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
16.

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.

Metzner KJ, Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Hirsch HH, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

AIDS. 2014 Sep 24;28(15):2231-9. doi: 10.1097/QAD.0000000000000397.

17.

Deteriorating renal function and clinical outcomes in HIV-positive persons.

Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD.

AIDS. 2014 Mar 13;28(5):727-37. doi: 10.1097/QAD.0000000000000134.

PMID:
24983543
18.

Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide.

Kouyos RD, Rauch A, Braun DL, Yang WL, Böni J, Yerly S, Klimkait T, Aubert V, Shah C, Kovari H, Calmy A, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (SHCS).

J Infect Dis. 2014 Nov 15;210(10):1555-61. doi: 10.1093/infdis/jiu315. Epub 2014 Jun 18.

19.

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.

Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD.

Infection. 2014 Aug;42(4):757-62. doi: 10.1007/s15010-014-0630-4. Epub 2014 Jun 6.

20.

Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations.

Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group.

HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19.

Supplemental Content

Loading ...
Support Center